In short
Clinical trials investigating IMMUNOSTEM are studying a first-in-human gene therapy approach for early type 1 diabetes. The trial is mainly designed to check safety, with a small group of patients taking part in a phase 1/2 study. It also looks at early signs of whether the treatment can be tested further.
Key points
- Clinical trials investigating IMMUNOSTEM are focused on early type 1 diabetes. The available study is a first-in-human, phase 1/2 trial with 15 planned participants. It is testing a gene therapy made from the patient’s own stem cells. The main goal is safety, including checks for adverse events, serious adverse events, vital signs, and lab tests. The study also uses an independent safety review after the first follow-up point. This is an early research step to see whether the treatment can move forward.
Trial overview
The available clinical trial for IMMUNOSTEM is a first-in-human study in people with early type 1 diabetes. It is an interventional trial, which means researchers are giving a treatment and then measuring what happens.
The trial title says it is testing a gene therapy using the patient’s own stem cells to treat early type 1 diabetes. The study brief summary says the main objective is to evaluate study treatment safety.
Who is being studied
The condition being studied is type 1 diabetes, specifically early disease. This means the trial is aimed at people who are in the early stage of this condition, not the general population.
The planned enrollment is 15 patients, so this is a small early trial. Small studies like this are common when a treatment is being tested for the first time in people.
What the study tests
The intervention is described as autologous CD34+ HSPCs transduced ex vivo with a LVV encoding the hPD-L1 cDNA, given by intravenous use. In simple words, the study uses the patient’s own stem cells, changes them in a laboratory, and gives them back through a vein.
This article does not go beyond the trial data to explain how the treatment works, because the source information focuses on the study design and safety goals.
Phase and study size
The trial is in phase 1/2. Phase 1 studies usually look first at safety, while phase 2 studies look more closely at early signs of whether a treatment may be worth testing further.
The study is authorised and has a planned enrollment of 15 patients. This suggests an early development program with careful monitoring.
Main outcomes and safety checks
The primary endpoint is safety. The trial will measure the number and description of adverse events, which are unwanted medical problems that happen during the study.
Safety will also be checked using vital signs, laboratory tests, and the frequency and severity of adverse events and serious adverse events. Serious adverse events are more severe problems, such as those that are life-threatening or need hospital care.
Safety will be assessed over the first 3, 12, and 24 months of follow-up in the pilot phase. The data safety monitoring board, or DSMB, will review the pilot safety results at 3 months before the study can continue to the next stage.
What the status means
The trial status is Authorised. This means the study has been approved to move forward, but the source data do not show final results yet.
Because this is an early trial, the main question is whether the treatment can be given safely to people with early type 1 diabetes. The trial is not presented in the source as a completed study, so there are no outcome results to report yet.